Program
vutiglabridin
Also written as “HSG4112” and “Vutiglabridin”.
Its studies are mostly in Obesity · Parkinson Disease · Osteoarthritis, Knee, led by Glaceum.
Furthest: phase 2, since Jan 5, 20227 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Glaceum | 71 open or running | phase 2since Jan 5, 2022 | Dec 16, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2020First study: phase 1 study in ObesityFirst studyNCT04703764 · 40 enrolled · South Korea
- Jan 18, 20212 phase 1 studies in ObesityNCT04733001, NCT04732988
- Jan 5, 2022Phase 2 study in ObesityNCT05197556 · 81 enrolled · Korea, Republic of
- Mar 25, 2022Phase 1 study in ObesityNCT05310032 · 36 enrolled · Korea, Republic of
- Mar 18, 2024Phase 2 study in Parkinson DiseaseNCT06329141 · 99 enrolled · South Korea
- Feb 20, 2025Phase 2 study in Osteoarthritis, KneeNCT06845553 · 60 planned · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06845553Osteoarthritis, Knee · South Korea | 2 | Recruiting | Jul 31, 2026 | 60 |
| NCT06329141Parkinson Disease · South Korea | 2 | Completed | Dec 16, 2025 | 99 |
| NCT05310032Obesity · Korea, Republic of | 1 | Completed | Dec 12, 2022 | 36 |
| NCT05197556Obesity · Korea, Republic of | 2 | Completed | Dec 31, 2022 | 81 |
| NCT04732988Obesity · Korea, Republic of | 1 | Completed | May 24, 2021 | 90 |
| NCT04733001Obesity · Korea, Republic of | 1 | Completed | Feb 10, 2021 | 12 |
| NCT04703764Obesity · South Korea | 1 | Completed | Jan 20, 2022 | 40 |
How it is read
Names in the registry
- “HSG4112”, 5 entries
- “Vutiglabridin”, 2 entries
Codes read as this program: HSG4112.
Conditions, from the studies’ own filings
- Obesity, 5 studies
- Parkinson Disease, 1 study
- Osteoarthritis, Knee, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.